Chemotherapy of lung cancer. by Papac, R. J.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 54 (1981), 283-292
Chemotherapy of Lung Cancer
ROSE J. PAPAC, M.D.
Chief, Hematology/Oncology Service, Veterans Administration Medical Center,
West Haven, Connecticut, and Associate Professor ofMedicine, Department of
Internal Medicine, Yale University School ofMedicine, New Haven, Connecticut
Received April 30, 1981
The potential for substantial improvement in the outcome of patients with carcinoma of the
lung seems most likely to develop in the field of chemotherapy. In the past decade, striking
advances in the management of small cell carcinoma have yielded higher response rates and
longer survival. While the greatest improvement can be predicted for patients whose disease is
limited in extent, combination chemotherapy and combined modality therapy generally are
effective in causing tumor regression for the majority of patients. About 20 percent of patients
with disease limited to the thorax and lymph nodes will survive two years.
In non-small cell tumors, response rates are improved with intensive drug combinations,
although the majority of cases are unresponsive to present regimens. Careful staging and
evaluation ofpatients indicates that patients with good performance status and limited extent of
disease appear to obtain the most benefit from intensive treatment. The considerable morbidity
of some treatments often influences the choice for or against chemotherapy in patients with
non-small cell carcinomas.
For the future, problems of particular interest will be in investigation of factors-biologic,
pharmacokinetic, immunologic-that are related to the failure to cure small cell carcinoma, the
most therapeutically responsive pulmonary tumor. Additionally, in the non-small cell tumors,
more effective therapies as well as clarification of the basis for relative resistance to cytotoxic
agents are areas for intensive investigation.
In the treatment of lung cancer, chemotherapy has become a generally accepted
and widely applied therapeutic modality. Since the majority of patients with this
disease are not cured by surgery or radiotherapy, and also because many cases
present with advanced stages of disease, chemotherapy is regarded as the most
promising approach to the ultimate control of lung cancer.
In small cell tumors, significant advances intherapy have produced striking results
[1-10]. The non-small cell tumors, however, have remained relatively refractory to
treatment [11-15].
The premise upon which chemotherapy is based is that oferadication of tumor by
cytodestruction. Optimally, effective therapy should demonstrate selective toxicity to
tumor cells with little or tolerable damage to normal tissues. In practice, this has been
difficult to achieve. Drug treatment has evolved, however, from empiric considera-
tions of cell kinetics, the pharmacologic basis ofantineoplastic agents, and metabolic
aspects of tumor growth [16-18].
In the past decade, the use oftwo or more antineoplastic agents, simultaneously or
in close succession, has proved highly effective in diseases such as acute leukemia,
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All rights of reproduction in any form reserved.Hodgkin's disease, and breast cancer [19-22]. The rationale for combination che-
motherapy is based upon the concept that the effectiveness of antitumor agents may
be enhanced by concurrent and sequential inhibition ofmetabolic pathways for DNA
biosynthesis [23], which could yield additive or synergistic effects. Additionally, it is
possible that the use of multiple agents, by analogy to antibiotic usage in the
management of infectious disease, could reduce the development of drug resistance
[24]. In actual clinical practice, however, combinations ofdrugs are generallyselected
on the basis of known effectiveness of each component drug in the disease and
divergent toxicity of the component drugs.
Despite the widespread use of combination chemotherapy, relatively little atten-
tion has been given to possible detrimental results. Drug interactions could prove to
be antagonistic, so that agents, known to be effective when used singly, would
become ineffective in combination. There is also the potential for ineffectiveness ofa
known active compound, when used in combination, due to the dose-response
requirements of the individual agent. Combinations generally include doses lower
than those used when compounds are administered singly. Certain agents, to be
effective, may require higher doses to elicit a response than those doses employed in
combinations. In the design of clinical trials with drugs in combinations, considera-
tion of these possible adverse effects is merited.
NON-SMALL CELL CARCINOMA
In evaluating antitumor response in patients with non-small cell carcinoma, the
effectiveness of treatment may be assessed in relation to cell type and stage ofdisease
(Table 1) [11]. Factors such as performance status, complicating illness, and age are
important determinants in the outcome [25,26].
Early studies with single agent chemotherapy in cases with advanced disease
suggested generally low response rates in patients with epidermoid carcinoma and a
TABLE 1
Response of Bronchogenic Carcinoma to Single Agent Chemotherapy by Cell Type
Drug Epidermoid Small Cell Adeno. Large Cell
CCNU + + + + + +
Mechlorethamine + + + + + +
Methotrexate + + + + + + + +
Procarbazine + + + + + + +
Cyclophosphamide + + + + + + + +
Adriamycin + + + +
I-ME-1-Nitrosourea + + + +
Bleomycin + 0 +
Hexmethylmelamine + + + + +
Mitomycin C 0 0 + +
Platinum diamminodichloride + + + + 0 0
VP-16-123 0 ++ + 0 0
5-Fluorouracil + 0 0 +
Vincristine 0 + + 0 0
Vindesine + 0 0 0
m-AMSA 0 0 + 0
+ + +, response > 40 percent of all patients
+ +, 20 percent-39 percent
+, 10 percent-19 percent
0, < 10 percent
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negligible rate of response in patients with adenocarcinoma arising in the lung [27].
Subsequent cornpilation of results of treatment show great variability in response
rate. To some extent this is a consequence of differing criteria in evaluating response,
as well as small numbers in individual series. Often the determination of response in
pulmonary lesions is based upon indirect measurements-the chest X-ray lesion may
be a manifestation not only of tumor but of associated infection, inflammation, and
perhaps bleeding. There are certainly major areas of serious question regarding
efficacy of treatment with cytotoxic drugs in non-small cell carcinoma.
Recent data is based upon greater uniformity in assessment with respect to staging
and criteria for response. There is a trend toward multi-modality intensive treatment
of patients with locally unresectable non-small cell tumors [28,29]
A recent approach to the management of inoperable cases of lung carcinoma has
been to combine chemotherapy with "reductive" surgery; that is, to surgically remove
tumors following regression with chemotherapy. Preliminary data are encouraging
[29]. Reducing the bulk of the tumor is theoretically advantageous as a means of
rendering additional cytotoxic therapy more effective.
In patients with non-small cell carcinoma with advanced disease, various drug
combinations are reported to induce tumor regression considered superior to that
achieved with single agents, although few controlled trials comparing single agents to
drug combinations have been carried out. Laing [30], in a randomized study, found
that combination chemotherapy was associated with shorter median survival than
single agent therapy or a control group (untreated), but better symptomatic control
of the disease developed in survivors of combination chemotherapy.
Intensive therapy with drug combinations generally yields response rates higher
than those reported in the past. However, responses are seldom complete. Survival
times vary from three to ten months, and rarely exceed one year [31-37]. An
exception is the trial of Egan et al. in which median survival of 17 months was
achieved [28].
Table 2 summarizes data from some recent selected clinical trials in non-small cell
carcinoma of the lung. It is apparent that high response rates in some series are not
verified in subsequent trials involving larger numbers of patients [12,34,35,38].
Additionally, there is often serious morbidity and occasional lethal complications
associated with intensive therapy. Nevertheless, numerous other regimens are in the
process of clinical trial or reporting in an attempt to find therapies of greater benefit
and less toxicity.
Preliminary studies with newer agents, vindesine, m-AMSA, the acridine dye
derivative 4'-9-acridinyldamino-methane-sulfone-M-anisidine, and maytansine sug-
gest that they may exert anti-tumor effects in non-small cell carcinoma [42-45].
Vindesine is being included in current trials of combined therapy for lung neoplasms
[39].
In randomized and in sequential trials, there does not appear to be a clear
advantage for intensive treatment of non-small cell carcinoma of the lung, as
compared to single agent therapy [13,14,30]. Careful staging and evaluation of
factors that influence response rate appear to identify patient groups who benefit
from treatments-those with limited extent of disease and good performance status.
Non-small cell tumors remain unresponsive to chemotherapy in the majority of
cases. In the individual patients, the very considerable morbidity of treatment
(although tolerable in most instances) must be a major factor influencing the choice
for or against chemotherapy for this disease.
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TABLE 2
Recent Results of Treatment of Non-Small Cell Carcinoma of the Lung
Median
No. of Cell Survival
Treatment Patients Type Response (months) Toxicity
CTX, A, P, TRT [281 27 adeno 15/27(ICR) 17 leucopenia 25/34
randomized with
CTX, A, D, TRT
7
28
6
large cell
adeno
large cell
1/7
12/28(2CR)
4/6
thrombopenia 5/34
7 leucopenia 25/34
thrombopenia 6/34
cardiotoxicity 1/60
nausea, vomiting 68/68
renal toxicity 12/68
TRT [25]
versus
TRT and Hu, CCNU
M, A, CTX, CCNU [12]
(MACC)
M, A, CTX, CCNU [38]
(MACC)
CTX, A, Mi [31]
(MAC)
CTX, A, M, F [33]
CTX, A, P, V [34]
(CAPV)
M, A, CTX, CCNU, V
(36] (MACCV)
CTX, A, P, V [35]
(CAPV)
21 adeno
79 squam
31 large cell
20 adeno
74 squam
32 large cell
43 adeno
43 squam
12 adeno
13 squam
30 adeno
6 large cell
18 adeno
9 squam
7 large cell
8 adeno
15 squam
9 large cell
9 adeno
16 squam
5 large cell
2 adeno
12 squam
4 large cell
NA 6 nausea, vomiting 15/38
NA 7 leucopenia < 3,000 10/38
NA 8 thrombopenia < 100,000
17/38
NA 6 nausea, vomiting 79/93
NA 7 stomatitis 29/93
NA 8 leucopenia 42/93
thrombopenia 26/93
lethal outcome 4/93
1/43
4/43
3/12
3/13
7/30
7/18(3CR)
2/9
1/7
6/6(1CR)
13/15(2CR)
3/9
3/9
4/16
1/5
0/2
3/12(1CR)
0/4
3 leucopenia < 1,000 11/43
4 thrombopenia < 25,000
5/43
stomatitis 3/43
liver disfunction 2/43
lethal outcome 2/43
7* leucopenia < 2,000 15/30
cardiotoxicity 1/30
lethal outcome 2/30
9* leucopenia < 2,000 10/30
nausea, vomiting 14/30
stomatitis 6/30
7 leucopenia, life
10 threatening 4/48
5 nausea, vomiting 12/48
stomatitis 12/48
liver disfunction 4/48
renal toxicity 12/48
nausea, vomiting 35/35
diarrhea 15/35
leucopenia < 2,000 5/35
thrombopenia < 100,000
5/35
7
4
6
6
leucopenia < 2,000 15/30
lethal outcome 2/30
nausea, vomiting 12/18
leucopenia < 1,000 2/18
thrombopenia < 25,100
1/18
lethal outcome 1/18
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TABLE 2-Continued
Median
No. of Cell Survival
Treatment Patients Type Response (months) Toxicity
CTX, CCNU, M 144]
A, P
CTX, Fu, CCNU [26]
Fu, Mi, V [371
HEXA, Mi [391
CTX, P, Vi [40]
CTX, A, P [41]
56 adeno
32 large cell
56 adeno
21 large cell
8/56
6/32
4/56
1/21
23 adeno 5/23(1CR)
43 adeno
10 large cell
24 not
specified
29 adeno
6 squam
43 adeno
39 squam
26 large cell
17/43
4/10
4/24
8/29
2/6
13/43
12/39
8/26
5
5
thrombopenia 12/88
4 thrombopenia, life
4 threatening 13/76
leucopenia, life
threatening 1/76
9 nausea, vomiting 5/23
leucopenia < 1,000 7/31
thrombopenia < 100,000
20/31
6 vomiting 4/56
thrombopenia < 100,000
14/56
leucopenia < 3,000 7/56
lung toxicity 1/56
lethal outcome 2/56
5 thrombopenia < 100,000
6/24
nausea, vomiting 3/24
stomatitis 1/24
lethal outcome 1/24
renal toxicity 9/24
nausea
9+ life threatening
4++ toxicity 12/90
*responders only; 'limited disease; "extensive disease
NA = data not available; CTX = cyclophosphamide; A = adriamycin; P = cis platinum;
TRT = thoracic radiotherapy; D = DTIC; HEXA = hemamethylmelamine; Hu = hydroxyurea;
Fu = fluorouracil; M = methotrexate; F = folinic acid; V = vincristine; Vi = vindesine;
Mi = mitomycin; CR = complete response; adeno = adenocarcinoma; squam = squamous cell car-
cinoma
SMALL CELL CARCINOMA
Small cell carcinoma, once considered one of the most rapidly lethal neoplasms of
man, is the type of pulmonary carcinoma most responsive to cytotoxic therapy.
Single agents, notably alkylating agents, are effective in inducing tumor regression in
about 25-30 percent of cases, although responses are generally brief [11,27]. As in
other neoplastic diseases, current trends are toward intensive treatment regimens,
including use of multiple drugs, cyclic treatment offrom six to 24 months' duration
and combined modality usage, with both radiation therapy and chemotherapy.
Concomitant with increased interest in the therapeutic management of small cell
carcinoma has been the development of sophistication in defining the extent of the
disease and assessing the impact of clinical parameters upon the outcome. The
predominant factor affecting survival appears to be the extent ofdisease at the time
of diagnosis [1,46]. Patients who have disease confined to the thorax and adjacent
287lymph node sites are considered to have limited disease. With one exception [47],
clinical studies demonstrate improved survival for patients with limited extent of
disease, as compared to those cases with more disseminated disease, classified as
extensive stage of disease. Attempts to identify factors other than extent of disease
that may influence prognosis have not been definitive. Recent publications suggest
that patients with cerebral metastasis have better survival than those with other
metastatic sites [48]; patients with bone marrow involvement and particularly those
with associated peripheral blood cytopenias have shortened survival [49]. Patients
with a solitary extra pulmonary focus of metastasis may have a more favorable
outcome than those with widespread metastases [50].
Numerous drugs have demonstrated significant antitumor effects in small cell
carcinoma of the lung (Table 1) [1,11]. Following the demonstration ofthe effective-
ness of alkylating agents, the use ofcyclophosphamide following radiation treatment
to the primary tumor was assessed to determine whether survival could be favorably
influenced [51]. Subsequently, drug combinations came into widespread clinical use
as a consequence of studies in small numbers of cases suggesting increased response
rate and longer survival [52,53]. Most of the clinical trials utilized survival datafrom
published reports-few controlled studies with less intensive regimens and single
agent treatment have been carried out. Nevertheless, the results achieved with inten-
sive therapeutic regimens are impressive, as reviewed by Greco et al. [9] (Table 3).
In a randomized study reported in 1975 [54], Laing compared a four-drug
combination to the use of radiotherapy in patients with both limited and extensive
TABLE 3
Selected Therapy and Survival in Limited-Stage Small Cell Lung Cancer
Median One-Year
Patients Survival Survival
Regimen (n) (wk) (No) Reference
No specific 31 14 7 [14]
therapy
Surgery* 270 - 19 [16-19]
Radiotherapy* 235 25 20 [5,20-22]
Radiotherapy
plus
1 CTXt 27 31 38 [21]
2 CTX, VCRt 23 50 50 [23]
3 CTX, VCR, 108 52 50 [25]
ADRt
4 CTX, VCR, 19 78 70 [28]
ADR BCGt
5 CTX, VCR, 16 76 80 [35, 36]
ADRi
6 CTX, VCR 32 Not 75 [9]
ADRt reached
*Mean values of several studies
tRadiotherapy given after starting chemotherapy or "sandwiched" between chemotherapy
i Radiotherapygivenconcomitantlywithchemotherapy. CTX-cyclophosphamide; VCR-vincristine;
ADR -doxorubicin (Adriamycin); BCG -Bacillus Calmette Guerin
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stages of small cell lung carcinoma. In this trial,
the morbidity of the radiotherapy patients was related to metastatic disease; in the chemotherapy patients, there was symptomatology related to the primary tumor. He suggested that optimal treatment could be a judicious combination of both modalities.
In practice,
most trials recently have utilized this approach. For patients with limited extent of disease, the median
survival is generally
from
to months;
it is estimated that
20 percent of such cases
will survive two years [1].
The combined modality approach includes "prophylactic" cranial irradiation so
designated because the rationale is to prevent the development of cerebral metastases. In two reports [55,56], this procedure has not been effective,
but generally the
incidence of brain metastasis is diminished in patients receiving cranial irradiation
early in the course of management [57]. Recently,
low dose abdominal irradiation has
been included combined modality regimens,
but its role is to be determined [56].
Drug
combinations are generally used in small cell carcinoma include
from two six agents. The use of six agents simultaneously appears to offer no
therapeutic advantage [58]. Whether the use of alternating combinations will reduce
the development
of drug resistance and prolong survival has been assessed by several
investigators without clear evidence of benefit.
There has been an attempt to define the optimal number of cycles needed to
achieve maximum response, and it appears that there is no advantage associated with
more six drug cycles [59]. Presently,
in the combined modality approach, drug
treatment precedes
and follows radiotherapy to the primary tumor [60]. Cranial
irradiation is often administered during the thoracic treatment.
Despite
these innovations in management,
little improvement has developed in
survival response rates. The morbidity of increasingly intensive treatment is
significant, so that some of the assumptions regarding the efficacy of this approach
are being questioned [61].
A recent controlled trial comparing single agent chemotherapy (cyclophospha-
mide)
irradiation combination chemotherapy with irradiation in both limited
and extensive stage disease found no survival difference in the groups [62]. The
response
were higher in the limited disease cases, however.
The observations are
consistent with our own findings.
Seventy patients
referred to the oncology service at the West Haven Veterans
Administration Hospital, over the past decade,
were studied to determine the survival
in relation types of therapy.
Median survival for the entire group 221
days.
Of 23 cases received solely radiotherapy (having refused additional
treatment), median survival was days, although a single patient survived eight
years
Of patients treated solely with single agent chemotherapy,
median survival days and a single case survived four years three months after
cyclophosphamide treatment. In cases given six cycles of combination chemother-
apy with cyclophosphamide, vincristine,
and methotrexate in addition to thoracic
irradiation,
median survival was days.
The differences are not statistically
significant.
Despite generally improved survival outcome for cases with limited extent disease,
few patients cured of the disease. Indeed,
careful scrutiny for metastatic
residual disease, probably yield evidence for lesser degrees of response-periodic
bronchoscopy suggests this [63].
It is unclear at this time whether the present
approach innovations will ultimately succeed in achieving cures
whether a plateau of responsiveness has developed.
The reasons for failure to achieve cure are presumed to be related to the
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development of resistance to therapy. Ifthis is correct, then the use ofmultiple agents
and alternating forms of cyclic agents may be extremely important. Thedevelopment
of more effective and varied cytotoxic agents could lead to control of the disease.
On the other hand, if the tumor, as Yesner [64] has postulated, arises from a cell
lineage capable of differentiation toward other cell lines, it is possible that drug
resistance is not the sole reason for failure to control the disease. Morphologic
differentiation to other cell types-squamous and adenocarcinoma-may result in
tumor cells unresponsive rather than resistant to treatment. Following therapy, as
well as prior to treatment, morphologic evidence of multiple cell types is well
documented [65].
Another possible mechanism in small cell carcinoma could be related to the tumor
model studied by Fidler [66]. Within the tumor, clones with variable metastatic
potential exist. Treatment could enhance or diminish tumor cell lines with selectivity
for sites and numbers of metastatic foci. Therefore, patients with limited extent of
disease have a biologically favorable form ofthe disease as compared with those with
extensive disease and treatment per se is not the most important determinant of
outcome.
The elucidation of biologic events in the course of treatment, that is, differentia-
tion, drug resistance, and host factors, will probably be the most significant factors
leading to ultimate control of the disease.
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